Novartis delivers strong operational performance in the first half of 2009
- Details
- Category: Novartis
- Pharmaceuticals an industry growth leader: Net sales up 12% (local currencies) in first half of 2009 on contributions from new products and expansion in all regions
- R&D maintains momentum: Anti-cancer therapy Afinitor introduced in the US, awaiting EU approval; new biologic Ilaris and OTC brand Prevacid 24HR gain US approvals; clinical trials set to start in July for A(H1N1) pandemic flu vaccine
- H1 2009 operating results advance well, but impacted negatively by currencies:
Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company's pending acquisition of Wyeth. The Commission's decision includes Pfizer's commitment to divest certain animal health assets in the EU.
Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease
- Details
- Category: Pfizer
Pfizer Inc has announced results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer's disease.(1,2) Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.(3)
GSK announces new commitments to fight HIV/AIDS in Sub-Saharan Africa
- Details
- Category: GlaxoSmithKline
Andrew Witty, Chief Executive Officer of GlaxoSmithKline, has announced a series of new initiatives targeted at improving research, development, and access to HIV/AIDS medicines for children in Sub-Saharan Africa and supporting healthcare for people living with HIV and AIDS.
Abbott and GSK to Collaborate on Molecular Diagnostic Test
- Details
- Category: Abbott
Abbott has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen. GSK's MAGE-A3 ASCI (Antigen Specific Cancer Immunotherapy) candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the Phase III clinical study MAGRIT, the largest lung cancer treatment study ever conducted.
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effientâ¢
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Effient™(prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI).
Bayer acquires exclusive rights to Bioton's insulin SciLin®
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton's Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acquires the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin® in China.
More Pharma News ...
- Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial
- AstraZeneca to Advance AZD3480 in ADHD
- Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US
- Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies
- Top 10 Tips for Staying Healthy When Money is Tight
- Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- GSK further extends its product portfolio in the Middle East and North Africa